NL-OMON32641尚未招募不适用
GM3 and insulin sensitivity - GM3 study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- written informed consent
- •- Caucasian
- •- able to keep a normal day and night rhythm during the study period (i.e. no shift work)
- •- stable weight for at least 3 months
- •- age 20-55 years
- •AND Inclusion criteria for healthy volunteers:
- •- 20 * BMI * 25 kg/m2
- •- fasting glucose level of < 5.6 mmol/L, in addition to a glucose level of < 7.8 mmol/L at 2 hours after intake of 75 g glucose (OGTT).;OR Inclusion criteria for obese subjects:
- •- BMI >30 kg/m2
- •- fasting glucose level of < 7 mmol/L, in addition to a glucose level of < 11.0 mmol/L at 2 hours after intake of 75 g glucose (OGTT).
- •- HOMA IR > 2.7
排除标准
- •- participation in an investigational drug trial within 90 days prior to our study
- •- history of or current abuse of drugs or alcohol (>14 U/week)
- •- vigorous physical activity
- •- family history of DM II
- •- familial dyslipidemia
- •- any medical condition except hypertension and dyslipidemia in the obese group
- •- use of any medication except for anti-hypertensives, excluding ACE-inhibitors/AII-antagonists
研究者
相似试验
尚未招募
不适用
GM3 and insulin sensitivity.Diabetes, obesity, insulin resistance,NL-OMON21599Academic Medical Center (AMC), Department of Endocrinology and Metabolism20
已完成
不适用
The effect of omega-3 in the treatment of gestational diabetesGestational diabetes mellitus.Diabetes mellitus in pregnancy, unspecifiedO24.9IRCT201312265623N16Kashan University of Medical Sciences56
已完成
不适用
The Association between glucotypes, insulin, and GLP-1 response in individuals with prediabetesPrediabetescontinuous glucose monitoring, prediabetes, OGTTTCTR20210729001Chulalongkorn University44
进行中（未招募）
1 期
Treatment with Metformin and growth hormone in children with a low birth weightEUCTR2018-000584-85-DKRigshospitalet24
已完成
不适用
A study in subjects with impaired glucose tolerance (IGT) to evaluate effects of AO-128 on prevention of type 2 diabetes mellitus (Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison)Impaired glucose tolerance (IGT)JPRN-UMIN000001109Takeda Pharmaceutical Company Limited1,782